Edetic acid

A chelating agent used mainly in the form of its salts for treatment of poisoning by substances such as heavy metals, cyanide, and Organophosphorus compounds. The salts form chelates with metal ions such as lead and mercury and promote the excretion of the metals from the body in a relatively nontoxic form.

Brands

Adult Dose

Neonatal

Paedriatic

Characteristics

. The Molecular Weight of Edetic acid is 292.90.

Contraindications

Edetic acid is contraindicated in conditions like Renal diseases,Anuria,Hepatitis,Pregnancy.

Effects

Edetic acid produces potentially life-threatening effects which include Cerebral edema, Encephalopathy, Renal tubular damage. which are responsible for the discontinuation of Edetic acid therapy.The signs and symptoms that are produced after the acute overdosage of Edetic acid include Broncho-constriction.

Indications

Edetic acid is primarily indicated in conditions like Anticoagulant, and can also be given in adjunctive therapy as an alternative drug of choice in Digitalis induced arrythmias, Hypercalcaemia.

Interactions

Edetic acid is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementInsulinSuccimerConcomitant administration of Succimer with other chelation therapy, such as CaNa2EDTA is not recommended.Zinc These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Interfrence

Urinanalysis Decreased Value of Urinary Alkaline Phosphatase Test

Risks

Drug should not be given to Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Storage

Warnings

Urine flow must be monitored throughout therapy which must be stopped if anuria or severe oliguria develop. The proximal tubule hydropic degeneration usually recovers upon cessation of therapy. Calcium EDTA must be used in reduced doses in patients with pre-existing mild renal disease. Patients should be monitored for cardiac rhythm irregularities and other ECG changes during intravenous therapy.

Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.